SCHEMBL21660596

SCHEMBL21660596

CC1(C)C=CC2=C(C=C1)NC(=O)CC2

nearest known ligand 0.37

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ CRBN Q96SW2 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22479922 0.82 — —
SCHEMBL25475096 0.72 — —
SCHEMBL21447622 0.68 FKBP5 (0.30) CRBN
SCHEMBL13068886 0.67 GSK3A (0.38) —
SCHEMBL21349639 0.66 MEN1 (0.31) —
SCHEMBL22694645 0.65 — —
SCHEMBL21447620 0.64 HTR2C (0.32) —
SCHEMBL22642201 0.64 — —
SCHEMBL23889389 0.63 GSK3B (0.31) —
SCHEMBL23395009 0.63 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023101710-A1 METHODS OF TREATING BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS AND ADDITIONAL THERAPEUTIC AGENTS VERU INC. (US) 2023-06-08 — — WO disclosed
WO-2020028593-A9 A METHOD OF TREATING ER MUTANT EXPRESSING BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) Oncternal Therapeutics, Inc. (US) 2021-03-18 — — WO disclosed
EP-3733170-A1 A METHOD OF TREATING ANDROGEN RECEPTOR (AR) -POSITIVE BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATOR (SARMS) Oncternal Therapeutics, Inc. (US) 2020-11-04 — — EP disclosed
WO-2020028593-A1 A METHOD OF TREATING ER MUTANT EXPRESSING BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) Oncternal Therapeutics, Inc. (US) 2020-02-06 — — WO disclosed
Send feedback